Matthew P. Miller - 15 Mar 2022 Form 3/A - Amendment Insider Report for Oncology Institute, Inc. (TOI)

Role
Chief Operating Officer
Signature
/s/ Mark Hueppelsheuser, Attorney-in-Fact for Matthew P Miller
Issuer symbol
TOI
Transactions as of
15 Mar 2022
Net transactions value
$0
Form type
3/A - Amendment
Filing time
23 Mar 2022, 19:21:14 UTC
Date Of Original Report
15 Mar 2022
Next filing
29 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TOI Earnout Shares 1 (Common Stock) 20,234 15 Mar 2022 Direct F1
holding TOI Earnout Shares 2 (Common Stock) 30,350 15 Mar 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted earn-out shares subject to forfeiture and unvested until such time that the Issuer's stock price reaches $12.50 per share for 20 days within any 30 consecutive trading days for the two-year period following the closing of the business combination of the Issuer, pursuant to that certain Agreement and Plan of Merger dated as of June 28, 2021, by and among DFP Healthcare Acquisitions Corp., Orion Merger Sub I, Inc., Orion Merger Sub II, LLC, and TOI Parent, Inc., that closed on November 12, 2021 (the "Business Combination"), subject to continued employment at such time.
F2 Represents restricted earn-out shares subject to forfeiture and unvested until such time that the Issuer's stock price reaches $15.00 per share for 20 days within any 30 consecutive trading days for the three-year period following the closing of the Business Combination, subject to continued employment at such time.

Remarks:

This Amendment updates Table I to reflect that Mr. Miller does not hold the 260,283 shares of common stock that were reported as held on his Form 3 filed March 15, 2022.